Logo image of DYN

DYNE THERAPEUTICS INC (DYN) Stock Fundamental Analysis

NASDAQ:DYN - US26818M1080 - Common Stock

14.22 USD
+0.98 (+7.4%)
Last: 9/5/2025, 8:09:14 PM
13.81 USD
-0.41 (-2.88%)
After Hours: 9/5/2025, 8:09:14 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DYN. DYN was compared to 541 industry peers in the Biotechnology industry. DYN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DYN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DYN has reported negative net income.
In the past year DYN has reported a negative cash flow from operations.
DYN had negative earnings in each of the past 5 years.
In the past 5 years DYN always reported negative operating cash flow.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

DYN's Return On Assets of -56.64% is in line compared to the rest of the industry. DYN outperforms 45.57% of its industry peers.
DYN has a Return On Equity (-72.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -56.64%
ROE -72.25%
ROIC N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

DYN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DYN has more shares outstanding
There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.53 indicates that DYN is not in any danger for bankruptcy at the moment.
The Altman-Z score of DYN (4.53) is better than 75.46% of its industry peers.
DYN has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of DYN (0.17) is worse than 67.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 4.53
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

DYN has a Current Ratio of 16.83. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
DYN's Current ratio of 16.83 is amongst the best of the industry. DYN outperforms 92.44% of its industry peers.
DYN has a Quick Ratio of 16.83. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
DYN's Quick ratio of 16.83 is amongst the best of the industry. DYN outperforms 92.44% of its industry peers.
Industry RankSector Rank
Current Ratio 16.83
Quick Ratio 16.83
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

DYN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.52%.
EPS 1Y (TTM)-7.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DYN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.11%
EPS Next 2Y-2.55%
EPS Next 3Y3.09%
EPS Next 5Y13.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DYN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y3.09%

More info and screens

0

5. Dividend

5.1 Amount

DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYNE THERAPEUTICS INC

NASDAQ:DYN (9/5/2025, 8:09:14 PM)

After market: 13.81 -0.41 (-2.88%)

14.22

+0.98 (+7.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners84.29%
Inst Owner Change4.19%
Ins Owners0.26%
Ins Owner Change0.65%
Market Cap2.02B
Analysts83.81
Price Target36.86 (159.21%)
Short Float %12.55%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.42%
Min EPS beat(2)-18.24%
Max EPS beat(2)-0.6%
EPS beat(4)1
Avg EPS beat(4)-10.75%
Min EPS beat(4)-33.5%
Max EPS beat(4)9.33%
EPS beat(8)2
Avg EPS beat(8)-9.41%
EPS beat(12)4
Avg EPS beat(12)-6.73%
EPS beat(16)5
Avg EPS beat(16)-7.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.99%
PT rev (3m)-23.24%
EPS NQ rev (1m)4.86%
EPS NQ rev (3m)13.28%
EPS NY rev (1m)8.46%
EPS NY rev (3m)5.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.54
P/tB 3.54
EV/EBITDA N/A
EPS(TTM)-3.86
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.53
OCFYN/A
SpS0
BVpS4.02
TBVpS4.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.64%
ROE -72.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.83
Quick Ratio 16.83
Altman-Z 4.53
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.78%
Cap/Depr(5y)173.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.57%
EPS Next Y-10.11%
EPS Next 2Y-2.55%
EPS Next 3Y3.09%
EPS Next 5Y13.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.85%
EBIT Next 3Y-6.67%
EBIT Next 5YN/A
FCF growth 1Y-105.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.99%
OCF growth 3YN/A
OCF growth 5YN/A